Compositions comprising a bacterial strain of the genus
The invention provides compositions comprising bacterial strains for treating and preventing neurodegenerative disorders.
1. A pharmaceutical composition comprising a dried bacteria strain of the species Megasphaera massiliensis,
wherein the bacteria strain comprises a 16S rRNA gene sequence that has at least 96% sequence identity to the polynucleotide sequence of SEQ ID NO: 2, as determined by a Smith-Waterman homology search algorithm using an affine gap search with a gap open penalty of 12, a gap extension penalty of 2, and a Blocks Substitution Matrix (BLOSUM) of 62,
and
a pharmaceutically acceptable excipient, diluent, or carrier.
2. The pharmaceutical composition of claim 1 , wherein the bacteria strain is present in the pharmaceutical composition in an amount that comprises from about 1×10 3 to about 1×10 11 colony forming units (CFU)/g of the bacteria strain with respect to the total weight of the pharmaceutical composition.
3. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is formulated for oral, rectal, nasal, buccal, sublingual, or subcutaneous administration.
4. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is formulated for delivery to an intestine of the subject.
5. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is encapsulated.
6. The pharmaceutical composition of claim 1 , wherein pharmaceutical composition comprises an enteric coating.
7. The pharmaceutical composition of claim 1 , further comprising an additional therapeutic agent.
8. The pharmaceutical composition of claim 1 , wherein the bacteria strain comprises a 16S rRNA gene sequence that has at least 99% sequence identity to the polynucleotide sequence of SEQ ID NO:2, as determined by a Smith-Waterman homology search algorithm using an affine gap search with a gap open penalty of 12, a gap extension penalty of 2, and a Blocks Substitution Matrix (BLOSUM) of 62.
9. The pharmaceutical composition of claim 1 , wherein the bacteria strain comprises a 16S rRNA gene sequence that is the polynucleotide sequence of SEQ ID NO:2.
10. The pharmaceutical composition of claim 1 , wherein the bacteria strain is the bacteria strain deposited under accession number NCIMB 42787.
11. A method of treating a neurological condition associated with neuroinflammation, oxidative stress, or neurodegeneration in a subject in need thereof comprising: administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of a bacteria strain of the species Megasphaera massiliensis , wherein the bacteria strain comprises a 16S rRNA gene sequence that has at least 96% sequence identity to the polynucleotide sequence of SEQ ID NO:2, as determined by a Smith-Waterman homology search algorithm using an affine gap search with a gap open penalty of 12, a gap extension penalty of 2, and a Blocks Substitution Matrix (BLOSUM) of 62, thereby treating the neurological condition associated with neuroinflammation, oxidative stress, or neurodegeneration in the subject.
12. The method of claim 11 , wherein the bacteria strain is the bacteria strain deposited under accession number NCIMB 42787.
13. The method of claim 11 , wherein administering comprises oral, rectal, nasal, buccal, sublingual, or subcutaneous administration.
14. The method of claim 11 , wherein the bacteria strain comprises a 16S rRNA gene sequence that has at least 99% sequence identity to the polynucleotide sequence of SEQ ID NO:2, as determined by a Smith-Waterman homology search algorithm using an affine gap search with a gap open penalty of 12, a gap extension penalty of 2, and a Blocks Substitution Matrix (BLOSUM) of 62.
15. The method of claim 11 , wherein the pharmaceutical composition is encapsulated.
16. The method of claim 11 , wherein the bacteria strain is dried.
17. The method of claim 11 , wherein the subject is human.